{
    "clinical_study": {
        "@rank": "164868", 
        "arm_group": [
            {
                "arm_group_label": "JUVEDERM\u00ae Ultra XC perioral lines", 
                "arm_group_type": "Experimental", 
                "description": "Perioral lines treated with JUVEDERM\u00ae Ultra XC"
            }, 
            {
                "arm_group_label": "Belotero Balance\u00ae perioral lines", 
                "arm_group_type": "Experimental", 
                "description": "Perioral Lines treated with Belotero Balance\u00ae"
            }
        ], 
        "brief_summary": {
            "textblock": "A prospective, randomized, controlled, multi-center study of the safety and effectiveness of\n      JUVEDERM\u00ae Ultra XC injectable gel versus Belotero Balance\u00ae for perioral lines"
        }, 
        "brief_title": "JUVEDERM\u00ae Ultra XC vs. Belotero Balance\u00ae for Perioral Lines", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Moderate to Severe Perioral Lines", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have moderate to severe perioral lines as assessed by the Investigator using the\n             4-point POLSS (none, mild, moderate, and severe)\n\n          -  Accept the obligation not to receive any other facial procedures or treatments at any\n             time during the study that are not study related\n\n        Exclusion Criteria:\n\n          -  Have lip tattoos, facial hair or scars that would interfere with visualization of the\n             lips and perioral area for the effectiveness assessments\n\n          -  Have dentures or any device covering all or part of the upper palate, and/or severe\n             malocclusion, dentofacial or maxillofacial deformities, or significant asymmetry of\n             the  perioral area, as judged by the Treating Investigator\n\n          -  Have a history of skin cancer\n\n          -  Is an active smoker\n\n          -  Has noticeable acne scarring, active inflammation, infection, cancerous or\n             precancerous lesion,  or unhealed wound in the mouth area\n\n          -  Have had an active oral herpes or cold sore within 12 months\n\n          -  Have undergone oral surgery or other dental procedures (e.g., tooth extraction,\n             orthodontia, or implantation) within 30 days prior to enrollment or be planning to\n             undergo any of these procedures during the study\n\n          -  Have undergone cosmetic facial or perioral area procedures [e.g., face-lift, or other\n             surgeries which may alter the appearance of the perioral area, including tissue\n             grafting, or tissue augmentation with silicone, fat, or other permanent fillers] or\n             be planning to undergo any of these procedures at any time during the study\n\n          -  Have undergone temporary or semi-permanent facial dermal filler injections (e.g.,\n             hyaluronic acid, calcium hydroxylapatite, L-Polylactic acid)  in the lower face\n             (below the orbital rim) within 24 months\n\n          -  Have received mesotherapy, or resurfacing (laser, photomodulation, intense pulsed\n             light, radio frequency, dermabrasion, chemical peel, or other ablative or\n             non-ablative procedures) within 6 months prior to entry in the study or be planning\n             to undergo any of these procedures at any time during the study other than study\n             related procedures.\n\n          -  Have begun use of any new over-the-counter or prescription, oral or topical,\n             antiwrinkle products in the treatment area within 90 days prior to enrollment or be\n             planning to begin use of such products at any time during the study. [NOTE: Use of\n             sunscreens and continued therapy with some cosmeceuticals (e.g., alpha hydroxyl\n             acids, glycolic acids, retinol, or retinoic acids) is allowed if the regimen was\n             established \u2265 90 days prior to enrollment]\n\n          -  Have had epilation (e.g. laser hair removal, electrolysis, threading, etc.)  in the\n             perioral area performed within 3 months\n\n          -  Have received treatment with botulinum toxin of any serotype for any indication in\n             the lower face  [below the infraorbital rims (IORs)]  within 1 year of the baseline\n             visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970397", 
            "org_study_id": "GMA-JUV13001"
        }, 
        "intervention": [
            {
                "arm_group_label": "JUVEDERM\u00ae Ultra XC perioral lines", 
                "description": "Up to 3.0 mLs JUVEDERM\u00ae Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).", 
                "intervention_name": "JUVEDERM\u00ae Ultra XC", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Belotero Balance\u00ae perioral lines", 
                "description": "Up to 3.0 mLs Belotero Balance\u00ae injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).", 
                "intervention_name": "Belotero Balance\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM\u00ae Ultra XC Injectable Gel Versus Belotero Balance\u00ae for Perioral Lines", 
        "overall_contact": {
            "email": "devicetrials@allergan.com", 
            "last_name": "Allergan Medical"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "4-point Perioral Lines Severity Scale (POLSS)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970397"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}